Study guide

3.1 Acute Decompensated Heart Failure & Staging

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

3.1 Acute Decompensated Heart Failure & Staging

Key Takeaways Explain This Topic AI

HFrEF (EF ≤40%), HFmrEF (EF 41-49%), and HFpEF (EF ≥50%) require distinct pharmacological strategies, though mineralocorticoid receptor antagonists (MRAs) and SGLT2 inhibitors demonstrate clinical benefit across the entire spectrum.

The Forrester Hemodynamic Classification categorizes patients into Warm/Dry (Subset I), Warm/Wet (Subset II), Cold/Dry (Subset III), and Cold/Wet (Subset IV) based on cardiac index (>2.2 L/min/m²) and PAOP (≤18 mmHg).

ACC/AHA Stages (A through D) reflect structural disease progression and cannot be reversed, whereas NYHA Functional Classes (I through IV) capture dynamic symptom severity and fluctuate with treatment.

Invasive hemodynamic targets during acute decompensation include maintaining a Cardiac Index >2.2 L/min/m², PAOP <15–18 mmHg, SVR 800–1200 dyn·s·cm⁻⁵, and SvO2 >65%.

Diuretic resistance is systematically managed with loop diuretic escalation, continuous IV infusions, or sequential nephron blockade (adding thiazide/metolazone) before initiating ultrafiltration.

Last updated: August 2026

3.1 Acute Decompensated Heart Failure & Staging

Acute Decompensated Heart Failure (ADHF) is a life-threatening clinical syndrome characterized by the rapid onset or worsening of heart failure symptoms and signs, requiring urgent medical evaluation and therapy. It represents the leading cause of hospitalization in patients over 65 years of age. For the AACN Cardiac Medicine Certification (CMC) examination, the clinical nurse must master the pathophysiologic mechanisms of heart failure phenotypes, dynamic classification systems, invasive hemodynamic profiling, and precision pharmacological decongestion.

Heart Failure Phenotypes & Pathophysiology

Heart failure is classified based on Left Ventricular Ejection Fraction (LVEF) into three distinct clinical phenotypes, each exhibiting unique pathophysiologic mechanisms, structural remodeling patterns, and response to guideline-directed medical therapy (GDMT):

Phenotype LVEF Criterion Primary Pathophysiology Key Structural & Functional Features

HFrEF (Reduced) ≤ 40% Systolic dysfunction; impaired myocardial contractility Eccentric remodeling, ventricular dilation, elevated end-systolic volume, reduced stroke volume

HFmrEF (Mildly Reduced) 41% – 49% Mixed systolic and diastolic dysfunction Variable LV dilation, mild contractility impairment; shares therapeutic responses with HFrEF

HFpEF (Preserved) ≥ 50% Diastolic dysfunction; impaired relaxation and stiff non-compliant LV Concentric remodeling/hypertrophy, elevated filling pressures, normal LV end-diastolic volume

Neurohormonal Activation & Remodeling

In response to reduced cardiac output or wall stress, the body activates compensatory neurohormonal pathways:

Renin-Angiotensin-Aldosterone System (RAAS): Decreased renal perfusion triggers renin release, generating Angiotensin II (causing systemic vasoconstriction and cardiac fibrosis) and Aldosterone (promoting sodium/water retention and myocardial stiffness).

Sympathetic Nervous System (SNS): Beta-1 receptor stimulation increases heart rate and contractility, while alpha-1 stimulation increases systemic vascular resistance (SVR). Chronic hyperadrenergic state leads to beta-receptor downregulation, direct cardiomyocyte toxicity, and lethal arrhythmias.

Natriuretic Peptide System (ANP/BNP): Ventricular stretch stimulates BNP release, promoting vasodilation, natriuresis, and RAAS inhibition. In chronic HF, endogenous natriuretic peptides are degraded by neprilysin, prompting the use of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs).

Endothelin-1 & Vasopressin (AVP): Promote intense arterial vasoconstriction and non-osmotic water reabsorption via V2 receptors in the renal collecting ducts, compounding hyponatremia and volume overload.

Heart Failure Staging vs. Functional Classification

Evaluating heart failure severity requires integrating structural staging with functional symptom grading. The AACN CMC exam frequently tests the critical distinction between the ACC/AHA Stages and the NYHA Functional Classes .

Classification System Focus & Nature Stages / Classes Clinical Definition

ACC/AHA Staging Structural disease development; Progressive & Irreversible Stage A At high risk for HF (HTN, CAD, Diabetes) without structural heart disease or symptoms

  • Stage B Structural heart disease present (prior MI, LVH, reduced LVEF) without symptoms (Pre-HF)
  • Stage C Structural heart disease with prior or current HF symptoms
  • Stage D Advanced/Refractory HF requiring specialized interventions (VAD, transplant, continuous inotropes)

NYHA Classification Symptom severity & physical capacity; Dynamic & Reversible Class I No limitation of physical activity. Ordinary activity does not cause fatigue, dyspnea, or palpitations

Class II Slight limitation of physical activity. Comfortable at rest, but ordinary activity causes symptoms

Class III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms

Class IV Inability to carry on any physical activity without discomfort. Symptoms present at rest

Exam Tip: A patient can move back and forth between NYHA Classes (e.g., from Class IV during acute decompensation to Class II following diuresis), but cannot move backward in ACC/AHA Stages . Once Stage C is reached, the patient remains Stage C regardless of symptom resolution.

Precipitating Triggers for Acute Decompensation

Identifying and addressing acute triggers is paramount in managing ADHF. Common precipitants are remembered using the CHAMP acronym alongside extended clinical triggers:

C - Acute Coronary Syndrome (ACS): Myocardial ischemia or infarction impairing contractility.

H - Hypertensive Emergency: Abrupt surge in afterload overwhelming LV performance.

A - Arrhythmias: Rapid atrial fibrillation (loss of atrial kick, shortened diastolic filling time) or ventricular arrhythmias.

M - Mechanical Causes: Acute mitral valve papillary muscle rupture, aortic dissection, or acute valvular failure.

P - Pulmonary Embolism / Pneumonia: Acute increase in RV afterload or systemic inflammatory/hypoxic stress.

Non-adherence & Medications: Dietary sodium indiscretion, fluid non-compliance, medication omission, or initiation of cardiotoxic/sodium-retaining drugs (NSAIDs, thiazolidinediones, non-DHP CCBs).

Loading diagram... Forrester Hemodynamic Subsets & Targeted Interventions

Forrester Hemodynamic Classification

Bedside evaluation of ADHF relies on categorizing perfusion status ("Warm" vs. "Cold") and congestion status ("Dry" vs. "Wet"). The Forrester Classification System utilizes two objective hemodynamic thresholds:

Cardiac Index (CI): Threshold for adequate perfusion is > 2.2 L/min/m² .

Pulmonary Artery Occlusion Pressure (PAOP): Threshold for congestion is > 18 mmHg .

Forrester Subset Perfusion & Congestion PAOP (mmHg) Cardiac Index (L/min/m²) Clinical Signs & Symptoms Primary Pharmacological Strategy

Subset I Warm & Dry ≤ 18 > 2.2 Compensation; clear lungs, warm extremities Optimize oral GDMT

Subset II Warm & Wet > 18 > 2.2 Pulmonary congestion, orthopnea, JVD, S3 gallop, warm skin IV Loop Diuretics ± IV Vasodilators (Nitroglycerin)

Subset III Cold & Dry ≤ 18 ≤ 2.2 Fatigue, cool extremities, narrow pulse pressure, elevated BUN/Cr, no rales Cautious IV fluids if PAOP <15; IV Inotropes if hypoperfusion persists

Subset IV Cold & Wet > 18 ≤ 2.2 Severe dyspnea, oliguria, hypotension, lactic acidosis, cool mottled extremities IV Inotropes (Dobutamine/Milrinone) + IV Diuretics ± Vasodilators / MCS

Invasive vs. Non-Invasive Hemodynamic Assessment

Accurate bedside assessment requires synthesizing non-invasive physical examination markers with invasive pulmonary artery catheter (PAC) data:

Non-Invasive Clinical Markers

Perfusion: Narrow pulse pressure (Systolic minus Diastolic < 25% of Systolic), cool distal extremities, delayed capillary refill (>3 seconds), altered mental status, worsening renal function (cardiorenal syndrome Type 1).

Congestion: Elevated Jugular Venous Pressure (JVP > 8 cm H2O), positive hepatojugular reflux, hepato-splenomegaly, pulmonary crackles/rales, peripheral edema, ascites.

Invasive Hemodynamic Targets

PAOP (PCWP): Target 14–18 mmHg in ADHF (elevated baseline pre-load required for non-compliant LV, but >18 mmHg causes pulmonary edema).

Central Venous Pressure (CVP): Target 8–12 mmHg (correlates with right atrial pressure and systemic venous congestion).

Systemic Vascular Resistance (SVR): Formula: [ (MAP - CVP) / CO ] x 80 . Target 800–1200 dynes/sec/cm⁻⁵ . SVR is typically elevated (>1500) in ADHF due to compensatory SNS activation.

Mixed Venous Oxygen Saturation (SvO2): Normal 65%–75% . An SvO2 <60% reflects heightened tissue oxygen extraction secondary to inadequate cardiac output.

Acute Diuresis & Decongestion Strategies

Intravenous loop diuretics (furosemide, bumetanide, torsemide) represent the cornerstone of therapy for Subset II and IV ADHF. Loop diuretics act on the thick ascending Limb of Henle by inhibiting the Na+/K+/2Cl- cotransporter.

Diuretic Dosing & Administration (The DOSE Trial Insights)

Initial Dosing: For diuretic-naive patients, start with IV furosemide 20–40 mg. For patients on chronic oral loop diuretics, the initial IV bolus dose should equal or exceed 1 to 2.5 times their total daily oral home dose (e.g., if on 40 mg oral furosemide daily, administer 40–100 mg IV furosemide).

Continuous vs. Bolus: High-dose IV loop diuretic strategies achieve more rapid decongestion without causing long-term worsening of renal function compared to low-dose strategies. Continuous IV infusions (e.g., furosemide 5–20 mg/hr following a loading bolus) provide steady drug delivery, minimizing peak-and-troughs and rebound sodium reabsorption.

Diuretic Spot Sodium Monitoring: Checking a spot urine sodium 2 hours post-diuretic bolus evaluates diuretic responsiveness. A urine Na+ < 50–70 mEq/L indicates diuretic resistance.

Diuretic Resistance Management

When standard loop diuretic escalation fails to achieve adequate net negative fluid balance (>1–2 liters/day), sequential nephron blockade is indicated: [IV Loop Diuretic (Furosemide/Bumetanide)]

  • +
  • [Thiazide-Like Diuretic (Oral Metolazone 2.5-10 mg OR IV Chlorothiazide 250-500 mg)]

Mechanism: Thiazides block the Na+/Cl- cotransporter in the distal convoluted tubule, preventing hypertrophied distal tubular cells from reabsorbing sodium escaping loop diuretic blockade.

Monitoring Priorities: Intense electrolyte monitoring is mandatory due to severe risks of hypokalemia, hypomagnesemia, hyponatremia, and acute prerenal azotemia.

Ultrafiltration (Aquapheresis)

Ultrafiltration involves mechanically removing isotonic plasma water across a semipermeable membrane driven by a hydrostatic pressure gradient.

Indications: Refractory fluid overload non-responsive to maximal sequential nephron blockade, or severe acute cardiorenal syndrome with diuretic failure.

Nursing Considerations: Fluid removal rates are typically set between 100–250 mL/hr to prevent intravascular depletion, hypotension, and clotting of the circuit. Hematocrit is monitored closely as an indicator of intravascular hemoconcentration.

  • Vasodilator & Inotropic Therapy in ADHF
  • Intravenous Vasodilators

Indicated in patients with acute congestion ( Warm & Wet or Cold & Wet with SBP > 90 mmHg) to rapidly reduce PAOP and SVR without increasing myocardial oxygen demand.

Nitroglycerin (IV):

Mechanism: Direct venodilator at low doses (< 100 mcg/min), reducing preload and PAOP. At high doses (> 100–200 mcg/min), causes arterial vasodilation, lowering SVR.

Indications: ADHF secondary to acute coronary ischemia or acute hypertensive pulmonary edema.

Nursing Considerations: Rapid tolerance (tachyphylaxis) develops within 24–48 hours. Monitor for headache and severe hypotension.

Sodium Nitroprusside (IV):

Mechanism: Potent, balanced arterial and venous vasodilator via direct nitric oxide donation. Significantly reduces SVR and PAOP, increasing stroke volume.

Indications: Severe hypertensive crisis with acute HF, acute severe mitral or aortic regurgitation.

Nursing Considerations: Requires continuous arterial line monitoring. Cyanide and Thiocyanate Toxicity Risk: Increased with prolonged infusion (>48 hours), high doses (>2 mcg/kg/min), or renal/hepatic impairment. Symptoms include metabolic acidosis, confusion, hyperreflexia, and thiocyanate levels >10 mg/dL.

Intravenous Inotropes

Indicated in patients with severe LV systolic dysfunction and evidence of low cardiac output / hypoperfusion ( Subset III Cold & Dry or Subset IV Cold & Wet ).

Dobutamine:

Mechanism: Synthetic catecholamine acting primarily as a Beta-1 adrenergic agonist (increases contractility and heart rate) with mild Beta-2 stimulation (peripheral vasodilation). Net effect: increased Cardiac Index and reduced SVR.

Dosing: 2.5–20 mcg/kg/min.

Nursing Considerations: May trigger tachyarrhythmias and increase myocardial oxygen demand. Less effective in patients receiving chronic beta-blocker therapy.

Milrinone:

Mechanism: Phosphodiesterase-3 (PDE-3) inhibitor . Prevents cyclic AMP breakdown in cardiomyocytes (increasing intracellular calcium and contractility) and vascular smooth muscle (causing potent veno- and arteriodilation). Known as an Inodilator .

Dosing: 0.125–0.75 mcg/kg/min (load omitted in acute settings to avoid severe hypotension).

Nursing Considerations: Has a prolonged elimination half-life (2–4 hours), excreted renally (requires dose adjustment in renal failure). Functionally effective even in the presence of beta-blockers because it acts downstream of the beta-1 receptor.